Keloid Scarring: Treatment and Pathophysiology

Queen Mary University of London

Overview

To clarify the mechanisms of Keloid scar formation. Elucidate the action and therapeutic value of 5-FU in Keloid scar treatment Identify the genetic link with Keloid scar formation. Quantify the psychological/social impact in keloid scarring patients

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Keloid Scar

Interventions

5- fluorouracilDRUG

5mg of 5FU injected per 1cm square, at 6 week intervals for 30 weeks = 6 sessions

radiotherapyRADIATION

after complete excision of keloid they have a single session of radiotherapy

TriamcinoloneDRUG

TAC 10mg in 1ml injected intralesional

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult ( \> 18 years old). * Keloid scarring present. * Able to understand and give informed consent. * Patients giving informed consent to donate keloidal or non-affected skin when that is redundant after a procedure (i.e. BBR, Abdominoplasty). * Patients with a strong familial pedigree of keloid scar formation. Exclusion Criteria: * Open wound at or proximity of the lesion * Infected lesion * Pregnant or planning pregnancy in the near future * Lactating (Breast Feeding) * Abnormal renal or liver function tests * Atrophic scars * Patient under 18 years of age * Immunocompromised * OR immunosuppressed

Locations (1)

Barts and the London NHS Trust

London, UK, United Kingdom

Outcomes

Primary Outcomes

Keloid Scar Reduction

Using a 3D scanner to observe the reduction of the scar volume measured in cubic centimetres

Time frame: 18 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.